First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial

@inproceedings{Arrieta2012FirstlineCW,
  title={First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial},
  author={Oscar Arrieta and Luis Alberto Medina and Enrique Estrada-Lobato and Norma Y. H{\'e}rnandez-Pedro and Geraldine Villanueva-Rodr{\'i}guez and Luis Manuel Mart{\'i}nez-Barrera and Eleazar O. Macedo and V L{\'o}pez-Rodr{\'i}guez and Daniel Motola-Kuba and Jos{\'e} Francisco Corona-Cruz},
  booktitle={British Journal of Cancer},
  year={2012}
}
Background:Chemotherapy based on platinum is the standard treatment for unresectable malignant pleural mesothelioma (MPM). Liposomal doxorubicin (LD) consists of pegylated phospholipid vesicles that encapsulate doxorubicin-enhancing liposome deposition in the tumour. We evaluated the toxicity profile and anti-tumour activity of cisplatin plus LD in untreated patients with MPM, as well as 99mTc-LD distribution in MPM lesions after chemotherapy administration.Methods:A total of 38 patients with… CONTINUE READING
9 Citations
36 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Similar Papers

Loading similar papers…